ClinVar Genomic variation as it relates to human health
NM_000342.4(SLC4A1):c.1199_1225del (p.Ala400_Ala408del)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000342.4(SLC4A1):c.1199_1225del (p.Ala400_Ala408del)
Variation ID: 17753 Accession: VCV000017753.21
- Type and length
-
Deletion, 27 bp
- Location
-
Cytogenetic: 17q21.31 17: 44258043-44258069 (GRCh38) [ NCBI UCSC ] 17: 42335411-42335437 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Apr 9, 2018 Nov 24, 2024 Dec 21, 2023 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_000342.4:c.1199_1225del MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000333.1:p.Ala400_Ala408del inframe deletion NM_000342.3:c.1199_1225del27 NC_000017.11:g.44258044_44258070del NC_000017.10:g.42335412_42335438del NG_007498.1:g.15066_15092del LRG_803:g.15066_15092del LRG_803t1:c.1199_1225del LRG_803p1:p.Ala400_Ala408del - Protein change
- -
- Other names
- -
- Canonical SPDI
- NC_000017.11:44258042:CGGCAGCCAGGACCTGGGGGCTGAATGC:C
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
- -
- Links
- Comment on variant
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
SLC4A1 | - | - |
GRCh38 GRCh37 |
697 | 709 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic (2) |
criteria provided, single submitter
|
May 6, 2021 | RCV000019329.28 | |
protective (1) |
no assertion criteria provided
|
Mar 1, 2009 | RCV000019330.32 | |
Pathogenic (3) |
criteria provided, multiple submitters, no conflicts
|
Dec 21, 2023 | RCV001377074.14 | |
Pathogenic (1) |
criteria provided, single submitter
|
Jan 27, 2022 | RCV001536118.4 | |
Likely pathogenic (2) |
criteria provided, multiple submitters, no conflicts
|
May 19, 2023 | RCV001807735.1 | |
Pathogenic (1) |
no assertion criteria provided
|
Oct 22, 2019 | RCV001849272.2 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Jan 27, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
BLOOD GROUP--DIEGO SYSTEM
BLOOD GROUP--WALDNER TYPE BLOOD GROUP--WRIGHT ANTIGEN Southeast Asian ovalocytosis Autosomal dominant distal renal tubular acidosis Cryohydrocytosis BLOOD GROUP--SWANN SYSTEM BLOOD GROUP--FROESE Malaria, susceptibility to Renal tubular acidosis, distal, 4, with hemolytic anemia Hereditary spherocytosis type 4
Affected status: unknown
Allele origin:
unknown
|
Fulgent Genetics, Fulgent Genetics
Accession: SCV001752834.2
First in ClinVar: Jul 18, 2021 Last updated: Dec 31, 2022 |
|
|
Pathogenic
(Oct 10, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Not provided
Affected status: unknown
Allele origin:
germline
|
Mayo Clinic Laboratories, Mayo Clinic
Accession: SCV001712909.1
First in ClinVar: Jun 15, 2021 Last updated: Jun 15, 2021 |
Number of individuals with the variant: 2
|
|
Likely pathogenic
(Jan 03, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Renal tubular acidosis, distal, 4, with hemolytic anemia
Affected status: yes
Allele origin:
germline
|
3billion
Accession: SCV002058603.1
First in ClinVar: Jan 15, 2022 Last updated: Jan 15, 2022 |
Comment:
This inframe deletion in the non-repeat region can change the length of the protein and disrupt protein function (PM4_M). The variant has been reported at … (more)
This inframe deletion in the non-repeat region can change the length of the protein and disrupt protein function (PM4_M). The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000017753). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000046, PM2_M). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. (less)
Clinical Features:
Hemolytic anemia (present) , Hepatosplenomegaly (present) , Relative macrocephaly (present)
|
|
Likely pathogenic
(May 19, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Renal tubular acidosis, distal, 4, with hemolytic anemia
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
unknown
|
Institute of Human Genetics, University of Leipzig Medical Center
Accession: SCV004027790.1
First in ClinVar: Aug 26, 2023 Last updated: Aug 26, 2023 |
Comment:
Criteria applied: PM5_STR,PM4,PM2_SUP
Clinical Features:
Renal insufficiency (present) , Renal tubular acidosis (present)
Sex: female
|
|
Pathogenic
(Sep 25, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Revvity Omics, Revvity
Accession: SCV003817041.2
First in ClinVar: Mar 04, 2023 Last updated: Feb 04, 2024 |
|
|
Pathogenic
(Dec 21, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV001574307.4
First in ClinVar: May 10, 2021 Last updated: Feb 20, 2024 |
Comment:
This variant, c.1199_1225del, results in the deletion of 9 amino acid(s) of the SLC4A1 protein (p.Ala400_Ala408del), but otherwise preserves the integrity of the reading frame. … (more)
This variant, c.1199_1225del, results in the deletion of 9 amino acid(s) of the SLC4A1 protein (p.Ala400_Ala408del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs769664228, gnomAD 0.02%). This variant has been observed in individual(s) with autosomal dominant ovalocytosis and/or autosomal recessive distal renal tubular acidosis (PMID: 1722314, 1737855, 7919393, 7949112, 14618420, 19229254, 24652967, 28188436, 31672324, 31959358; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 17753). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects SLC4A1 function (PMID: 7689982, 16107207). For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Pathogenic
(May 06, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Southeast Asian ovalocytosis
Affected status: unknown
Allele origin:
germline
|
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute
Additional submitter:
Shariant Australia, Australian Genomics
Accession: SCV003921806.2
First in ClinVar: May 06, 2023 Last updated: Nov 24, 2024 |
Comment:
Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Dominant negative and loss of function are … (more)
Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Dominant negative and loss of function are known mechanisms of disease in this gene and are associated with SLC4A1-related disease. Spherocytosis type 4 (MIM#612653) is caused by variants with a loss of function mechanism. Cryohydrocytosis (MIM#185020), distal renal tubular acidosis (dRTA) (MIM#1179800), dRTA 4 with hemolytic anemia (MIM#611590) and SA type ovalocytosis (SAO) (MIM#166900) are caused by variants with either a loss of function, or dominant negative mechanism (PMID: 27058983). (I) 0108 - This gene is associated with both recessive and dominant disease. Most reports for this gene are for dominant disease, however, individuals biallelic for variants causing SAO have the more severe phenotype, dRTA with hemolytic anemia (OMIM, PMID: 17557941). (I) 0213 - In-frame insertion/deletion in a non-repetitive region that has moderate conservation. (SP) 0252 - This variant is homozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (13 heterozygotes, 0 homozygotes). (SP) 0600 - Variant is located in the annotated anion exchange transporter domain (UniProt, DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been observed in many heterozygous individuals with SA type ovalocytosis, and is highly prevalent within South Asian populations (PMID: 30124986, PMID: 19229254, PMID: 7949112). Additionally, carriers of this variant have some resistance to all forms of malaria (PMID: 31364155, OMIM). It is highly likely to be lethal in homozygosity, where rare survivors demonstrate severe anaemia, hydrops and distal renal tubular acidosis (PMID: 24652967). (SP) 1102 - Strong phenotype match for this individual. (SP) 1209 - This variant has been shown to be both maternally and paternally inherited (biallelic) (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign (less)
|
|
Pathogenic
(Mar 01, 2009)
|
no assertion criteria provided
Method: literature only
|
OVALOCYTOSIS, SOUTHEAST ASIAN
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000039619.5
First in ClinVar: Apr 04, 2013 Last updated: Aug 29, 2020 |
Comment on evidence:
Following up on the demonstration by Liu et al. (1990) that a structurally and functionally abnormal band 3 protein shows absolute linkage with the SAO … (more)
Following up on the demonstration by Liu et al. (1990) that a structurally and functionally abnormal band 3 protein shows absolute linkage with the SAO phenotype (166900), Jarolim et al. (1991) demonstrated that the EPB3 gene in these cases contains a 27-bp deletion, resulting in deletion of 9 amino acids (codons 400-408) in the boundary of cytoplasmic and membrane domains of the band 3 protein. The defect was detected in all 30 ovalocytic subjects from Malaysia, the Philippines, and 2 unrelated coastal regions of Papua New Guinea, whereas it was absent in all 30 controls from Southeast Asia and 20 subjects of different ethnic origin from the United States. The lys56-to-glu mutation (109270.0001) was also found in all SAO subjects; however, it was detected in 5 of 50 control subjects as well, suggesting that it represents a linked polymorphism. Mohandas et al. (1992) likewise demonstrated the deletion of amino acids 400-408 in the boundary between the cytoplasmic and the first transmembrane domains of band 3. The biophysical consequences of the mutation was a marked decrease in lateral mobility of band 3 and an increase in membrane rigidity. Mohandas et al. (1992) suggested that the mutation induces a conformational change in the cytoplasmic domain of band 3, leading to its entanglement in the skeletal protein network. This entanglement inhibits the normal unwinding and stretching of the spectrin tetramers necessary for membrane extension, leading to increased rigidity. The same deletion of 9 amino acids was found by Tanner et al. (1991) in a Mauritian Indian and by Ravindranath et al. (1994) in an African American mother and daughter. All cases of SAO had been associated with the Memphis-1 polymorphism (109270.0001), which is found in all populations but is present at higher frequency in American Indian and African American populations. However, SAO had not previously been identified in African Americans. The band 3 deletion in Southeast Asian ovalocytosis may prevent cerebral malaria (611162), but it exacerbates malarial anemia and may also increase acidosis, a major determinant of mortality in malaria. Allen et al. (1999) undertook a case-control study of children admitted to hospital in a malarious area of Papua New Guinea. The 24-bp deletion, detected by PCR, was present in 0 of 68 children with cerebral malaria, compared with 6 (8.8%) of 68 matched community controls. Median hemoglobin levels were 1.2 g/dl lower in malaria cases with Southeast Asian ovalocytosis than in controls (P = 0.035), but acidosis was not affected. The band 3 protein mediates the cytoadherence of parasitized erythrocytes in vitro. The remarkable protection that the SAO variant affords against cerebral malaria may offer a valuable approach to a better understanding of the mechanisms of adherence of parasitized erythrocytes to vascular endothelium and the pathogenesis of cerebral malaria. The abnormal SAO protein does not mediate chloride transport (Groves et al., 1993), and homozygosity for the 9-amino acid deletion is apparently lethal (Liu et al., 1994). Yusoff et al. (2003) examined the incidence of SAO in Malays in Kelantan, Malaysia, who had distal renal tubular acidosis. SAO was identified in 18 of the 22 distal renal tubular acidosis patients (81.8%), but in only 2 of the 50 controls (4%). Yusoff et al. (2003) referred to the band 3 variant as a 27-nt deletion. In a population-based study of 19 individuals each from Japan, Taiwan, and Indonesia, Wilder et al. (2009) found the 27-bp deletion associated with the SAO trait in 4 of the Indonesian samples only. These 4 SAO chromosomes also carried the Memphis variant (109270.0001). The haplotype associated with the 27-bp deletion was also found in Japanese samples, but not in Taiwanese samples, which was a surprising finding since Taiwan was thought to be part of the Austronesian population expansion. The findings indicated that chromosomes related to Indonesian SAO alleles are not a major component of genetic diversity among aboriginal Taiwanese, and suggested that the SLC4A1 gene is subject to natural selection. (less)
|
|
protective
(Mar 01, 2009)
|
no assertion criteria provided
Method: literature only
|
MALARIA, CEREBRAL, RESISTANCE TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000039620.5
First in ClinVar: Apr 04, 2013 Last updated: Aug 29, 2020 |
Comment on evidence:
Following up on the demonstration by Liu et al. (1990) that a structurally and functionally abnormal band 3 protein shows absolute linkage with the SAO … (more)
Following up on the demonstration by Liu et al. (1990) that a structurally and functionally abnormal band 3 protein shows absolute linkage with the SAO phenotype (166900), Jarolim et al. (1991) demonstrated that the EPB3 gene in these cases contains a 27-bp deletion, resulting in deletion of 9 amino acids (codons 400-408) in the boundary of cytoplasmic and membrane domains of the band 3 protein. The defect was detected in all 30 ovalocytic subjects from Malaysia, the Philippines, and 2 unrelated coastal regions of Papua New Guinea, whereas it was absent in all 30 controls from Southeast Asia and 20 subjects of different ethnic origin from the United States. The lys56-to-glu mutation (109270.0001) was also found in all SAO subjects; however, it was detected in 5 of 50 control subjects as well, suggesting that it represents a linked polymorphism. Mohandas et al. (1992) likewise demonstrated the deletion of amino acids 400-408 in the boundary between the cytoplasmic and the first transmembrane domains of band 3. The biophysical consequences of the mutation was a marked decrease in lateral mobility of band 3 and an increase in membrane rigidity. Mohandas et al. (1992) suggested that the mutation induces a conformational change in the cytoplasmic domain of band 3, leading to its entanglement in the skeletal protein network. This entanglement inhibits the normal unwinding and stretching of the spectrin tetramers necessary for membrane extension, leading to increased rigidity. The same deletion of 9 amino acids was found by Tanner et al. (1991) in a Mauritian Indian and by Ravindranath et al. (1994) in an African American mother and daughter. All cases of SAO had been associated with the Memphis-1 polymorphism (109270.0001), which is found in all populations but is present at higher frequency in American Indian and African American populations. However, SAO had not previously been identified in African Americans. The band 3 deletion in Southeast Asian ovalocytosis may prevent cerebral malaria (611162), but it exacerbates malarial anemia and may also increase acidosis, a major determinant of mortality in malaria. Allen et al. (1999) undertook a case-control study of children admitted to hospital in a malarious area of Papua New Guinea. The 24-bp deletion, detected by PCR, was present in 0 of 68 children with cerebral malaria, compared with 6 (8.8%) of 68 matched community controls. Median hemoglobin levels were 1.2 g/dl lower in malaria cases with Southeast Asian ovalocytosis than in controls (P = 0.035), but acidosis was not affected. The band 3 protein mediates the cytoadherence of parasitized erythrocytes in vitro. The remarkable protection that the SAO variant affords against cerebral malaria may offer a valuable approach to a better understanding of the mechanisms of adherence of parasitized erythrocytes to vascular endothelium and the pathogenesis of cerebral malaria. The abnormal SAO protein does not mediate chloride transport (Groves et al., 1993), and homozygosity for the 9-amino acid deletion is apparently lethal (Liu et al., 1994). Yusoff et al. (2003) examined the incidence of SAO in Malays in Kelantan, Malaysia, who had distal renal tubular acidosis. SAO was identified in 18 of the 22 distal renal tubular acidosis patients (81.8%), but in only 2 of the 50 controls (4%). Yusoff et al. (2003) referred to the band 3 variant as a 27-nt deletion. In a population-based study of 19 individuals each from Japan, Taiwan, and Indonesia, Wilder et al. (2009) found the 27-bp deletion associated with the SAO trait in 4 of the Indonesian samples only. These 4 SAO chromosomes also carried the Memphis variant (109270.0001). The haplotype associated with the 27-bp deletion was also found in Japanese samples, but not in Taiwanese samples, which was a surprising finding since Taiwan was thought to be part of the Austronesian population expansion. The findings indicated that chromosomes related to Indonesian SAO alleles are not a major component of genetic diversity among aboriginal Taiwanese, and suggested that the SLC4A1 gene is subject to natural selection. (less)
|
|
Pathogenic
(Oct 22, 2019)
|
no assertion criteria provided
Method: literature only
|
Distal renal tubular acidosis
Affected status: yes
Allele origin:
germline
|
Yale Center for Mendelian Genomics, Yale University
Study: Yale Center for Mendelian Genomics
Accession: SCV002106696.1 First in ClinVar: Mar 28, 2022 Last updated: Mar 28, 2022 |
|
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Whole exome sequencing identified ATP6V1C2 as a novel candidate gene for recessive distal renal tubular acidosis. | Jobst-Schwan T | Kidney international | 2020 | PMID: 31959358 |
High-throughput sequencing contributes to the diagnosis of tubulopathies and familial hypercalcemia hypocalciuria in adults. | Hureaux M | Kidney international | 2019 | PMID: 31672324 |
Advances in understanding the pathogenesis of red cell membrane disorders. | Iolascon A | British journal of haematology | 2019 | PMID: 31364155 |
Molecular Diagnosis of Solute Carrier Family 4 Member 1 (SLC4A1) Mutation-Related Autosomal Recessive Distal Renal Tubular Acidosis. | Deejai N | Laboratory medicine | 2019 | PMID: 30124986 |
Clinical and molecular aspects of distal renal tubular acidosis in children. | Besouw MTP | Pediatric nephrology (Berlin, Germany) | 2017 | PMID: 28188436 |
Band 3, the human red cell chloride/bicarbonate anion exchanger (AE1, SLC4A1), in a structural context. | Reithmeier RA | Biochimica et biophysica acta | 2016 | PMID: 27058983 |
Homozygous Southeast Asian ovalocytosis is a severe dyserythropoietic anemia associated with distal renal tubular acidosis. | Picard V | Blood | 2014 | PMID: 24652967 |
Natural history of Southeast Asian Ovalocytosis during the first 3 years of life. | Laosombat V | Blood cells, molecules & diseases | 2010 | PMID: 20421175 |
Molecular population genetics of SLC4A1 and Southeast Asian ovalocytosis. | Wilder JA | Journal of human genetics | 2009 | PMID: 19229254 |
Inherited renal acidoses. | Fry AC | Physiology (Bethesda, Md.) | 2007 | PMID: 17557941 |
Trafficking defects of the Southeast Asian ovalocytosis deletion mutant of anion exchanger 1 membrane proteins. | Cheung JC | The Biochemical journal | 2005 | PMID: 16107207 |
High prevalence of Southeast Asian ovalocytosis in Malays with distal renal tubular acidosis. | Yusoff NM | Journal of human genetics | 2003 | PMID: 14618420 |
Prevention of cerebral malaria in children in Papua New Guinea by southeast Asian ovalocytosis band 3. | Allen SJ | The American journal of tropical medicine and hygiene | 1999 | PMID: 10403343 |
The homozygous state for the band 3 protein mutation in Southeast Asian Ovalocytosis may be lethal. | Liu SC | Blood | 1994 | PMID: 7949112 |
Southeast Asian ovalocytosis in an African-American family. | Ravindranath Y | Blood | 1994 | PMID: 7919393 |
Molecular and cellular biology of the erythrocyte anion exchanger (AE1). | Tanner MJ | Seminars in hematology | 1993 | PMID: 8434259 |
The expression of the abnormal human red cell anion transporter from South-East Asian ovalocytes (band 3 SAO) in Xenopus oocytes. | Groves JD | FEBS letters | 1993 | PMID: 7689982 |
Molecular basis for membrane rigidity of hereditary ovalocytosis. A novel mechanism involving the cytoplasmic domain of band 3. | Mohandas N | The Journal of clinical investigation | 1992 | PMID: 1737855 |
Band 3 Tuscaloosa: Pro327----Arg327 substitution in the cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic hemolytic anemia and partial deficiency of protein 4.2. | Jarolim P | Blood | 1992 | PMID: 1378323 |
Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis. | Jarolim P | Proceedings of the National Academy of Sciences of the United States of America | 1991 | PMID: 1722314 |
Molecular defect of the band 3 protein in southeast Asian ovalocytosis. | Liu SC | The New England journal of medicine | 1990 | PMID: 2146504 |
Resistance of Melanesian elliptocytes (ovalocytes) to invasion by Plasmodium knowlesi and Plasmodium falciparum malaria parasites in vitro. | Hadley T | The Journal of clinical investigation | 1983 | PMID: 6338046 |
click to load more click to collapse |
Text-mined citations for rs769664228 ...
HelpRecord last updated Nov 25, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.
NCBI staff reviewed the sequence information reported in PubMed 1737855 Fig. 2 to determine the location of this allele on the current reference sequence.